Generium Pharmaceutical

Celltrion continues to establish its frontrunner position in the omalizumab biosimilar race as the firm submits a biologic license application to the US Food and Drug Administration for its CT-P39, a

Aurobindo Pharma is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche unit Genentech and Novartis , CEO

Aurobindo Pharma Limited is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche Holding AG unit Genentech,

Selexis and Generium have announced the launch of their Genolar (omalizumab) biosimilar in Russia, with the rival to the Xolair asthma and urticaria treatment marking the pair’s third biosimilar to